Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an announcement.
Sichuan Kelun-Biotech said China’s drug regulator has accepted a new indication application for its core TROP2-directed antibody-drug conjugate sacituzumab tirumotecan, in combination with pembrolizumab, as a first-line therapy for certain PD-L1-positive, EGFR- and ALK-negative locally advanced or metastatic non-small cell lung cancer patients. The filing, supported by the positive Phase 3 OptiTROP-Lung05 trial, has entered priority review, marking the fifth sac-TMT indication under accelerated assessment and potentially shortening time to approval while reinforcing the drug’s position in frontline NSCLC treatment.
The OptiTROP-Lung05 study showed sac-TMT plus pembrolizumab achieved a statistically significant and clinically meaningful improvement in progression-free survival versus pembrolizumab alone, with a positive trend in overall survival, making it the first Phase 3 immunotherapy–ADC combination to meet its primary endpoint in first-line NSCLC. Sac-TMT already has four approved indications in China and has been out-licensed to MSD for markets outside Greater China, underscoring its rising strategic value and expanding commercial footprint in the global oncology landscape.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$526.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based biopharmaceutical company focused on developing antibody-drug conjugates and other innovative oncology therapies. Its core product sacituzumab tirumotecan (sac-TMT), a TROP2-directed ADC, targets advanced solid tumors including non-small cell lung cancer, breast cancer, gastric cancer and various gynecological and genitourinary cancers.
Average Trading Volume: 513,940
Technical Sentiment Signal: Buy
Current Market Cap: HK$109.8B
See more insights into 6990 stock on TipRanks’ Stock Analysis page.